Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS)

Trial Profile

High-Resolution Assessment of Coronary Plaques in a Global Evolocumab Randomized Study (HUYGENS)

Recruiting
Phase of Trial: Phase III

Latest Information Update: 14 Feb 2019

At a glance

  • Drugs Evolocumab (Primary)
  • Indications Acute coronary syndromes
  • Focus Registrational; Therapeutic Use
  • Acronyms HUYGENS
  • Sponsors Amgen
  • Most Recent Events

    • 20 Nov 2018 Planned End Date changed from 20 Jun 2021 to 8 Jun 2021.
    • 20 Nov 2018 Planned primary completion date changed from 20 Jun 2021 to 8 Jun 2021.
    • 05 Nov 2018 Planned initiation date (Estimated date of first participant enrollement) changed from 31 Oct 2018 to 30 Nov 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top